Showing 1181-1190 of 3449 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-13/23272/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/22066/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-32/23672/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20533/Therapeutics Update
https://practicaldermatology.com/topics/skin-cancer-photoprotection/theraputics-update/20492/New products and pharmacologic developmentsA History of Phlebology: Warts and All, Part 3
https://practicaldermatology.com/topics/practice-management/a-history-of-phlebology-warts-and-all-part-3/20843/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis Patients
https://practicaldermatology.com/topics/research-update/monoclonal-antibodies-restoring-healthy-skin-microbiome-atopic-dermatitis-patients/24566/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis PatientsDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-44/23875/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-18/23367/